AlphAIAlphAI — Financial news for AI agents
investing.comOCT 232 min read$ABBV

FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi

AbbVie (ABBV) received FDA approval for a subcutaneous induction regimen of Skyrizi for Crohn's disease. The regimen involves 720 mg doses at weeks 0, 2, 4, and 8, with maintenance doses every 8 weeks. The approval is based on Phase 3 trial results showing 56% clinical remission vs. 30% for placebo. The FDA also updated prescribing info to remove mandatory TB testing. Skyrizi is approved for several autoimmune diseases.

Original reporting
investing.com
Published Oct 23, 2026, 7:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 7:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The approval expands Skyrizi's label, potentially increasing AbbVie's revenue stream and market share in the IBD therapeutic area.

02

Market read

First‑report FDA approval for a new dosing regimen of a high‑growth drug, likely to move AbbVie's stock positively.

03

What to watch

Potential competition from biosimilars and the need for payer acceptance could temper the stock reaction.

Relevance 7/10Novelty 9/10Timing: pre‑market today

Background

AbbVie announced FDA approval for a new subcutaneous induction regimen for its Crohn's disease drug Skyrizi, including dosing details and trial results.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

FDA approval of a subcutaneous induction regimen for Skyrizi in Crohn's disease expands the drug's market and may boost AbbVie's sales.

Expected impact

potential upward pressure as investors price in expanded indication and sales opportunity

Evidence & confidence

The approval adds a new dosing option for a high‑growth biologic, addressing unmet patient needs and could increase market share.

Market effects

Sector

Biotech and IBD/IBD‑related stocks may see heightened interest as the approval signals broader acceptance of subcutaneous biologics.

Regional

U.S. healthcare sector could see a modest boost; European markets with AbbVie listings may react similarly.

Global

Adds to the pipeline momentum for biologics globally, potentially influencing competitor strategies.

Counterpoint

What could challenge this read

If pricing or reimbursement issues arise, the approval may not translate into significant revenue, limiting upside.

Key entities

  • company
    AbbVie

    US‑listed biopharma company (ticker ABBV) receiving FDA approval for Skyrizi.

  • regulator
    FDA

    U.S. Food and Drug Administration granting the approval.

Read at source← All news

StoryFDA approves subcutaneous induction regimen of AbbVie’s SKYRIZI for Crohn’s disease

Also covered by

5 outlets

Related articles

OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SK

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on positive Phase 3 AFFIRM trial results, showing superior clinical remission and endoscopic response at week 12 compared to placebo, especially in treatment-naïve patients. The subcutaneous form allows for at-home administration using an on-body injector.

gurufocus.com2 min
OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

AbbVie's SKYRIZI® (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on Phase 3 AFFIRM trial results showing superior clinical remission and endoscopic response at week 12 compared to placebo, with no new safety risks identified. The subcutaneous option allows for at-home treatment using an on-body injector.

news.abbvie.com3 min
OCT 23
$ABBVHigh

FDA approves AbbVie’s Crohn’s drug for home shots; 74% of patients with no prior advanced-treatment failure were in remission at week 12.

FDA approved AbbVie's subcutaneous SKYRIZI for Crohn's disease, allowing home administration. Phase 3 AFFIRM study showed 74% remission in patients without prior advanced therapy failure at week 12. Safety profile consistent with known risks. FDA also updated TB testing guidelines for SKYRIZI. According to AbbVie, this approval provides greater treatment flexibility. SKYRIZI is an IL-23 inhibitor approved for several immune-mediated diseases.

stocktitan.net2 min
OCT 23
$ABBVMedAI 8/10

AbbVie’s skin disease drug posts Phase III win as market competition heats up

AbbVie's lutikizumab met primary endpoints in Phase III INTREPID trial for hidradenitis suppurativa (HS), reducing flares and skin pain. 31.4% of patients achieved HiSCR75 vs. 23.4% on placebo. Analysts noted response rates were lower than expected, but AbbVie highlights the drug's potential. Competitors include Novartis' Cosentyx and UCB's Bimzelx. HS market projected to grow to $7.8bn by 2034, according to GlobalData.

clinicaltrialsarena.com2 min